Nazartinib (EGF816)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Nazartinib (EGF816), covering 2019-11-22 to 2019-11-22. Get the full timeline:
Most recent: Clinical Trial Update: Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations [Phase 3]